HENLIUS (02696): Futoxing (Citric Acid Phenyl Ethyl Alcohol Capsule) has been included in the National Medical Insurance Drug List.

Henlius (02696) announced that recently, Furtulin (palbociclib citrate capsules) has been included in the National Basic Medical Insurance, Maternity Insurance, and Work-related Injury Insurance Drug List (2025 Edition) under Category B. The indication for inclusion is for adult patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have experienced disease progression after previous endocrine therapy. The new National Medical Insurance Drug List will be officially implemented starting from January 1, 2026. Furtulin is an innovative CDK4/6 small molecule inhibitor licensed by the company. In May 2025, it was approved for marketing in China and the first approved indication was for adult patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have experienced disease progression after previous endocrine therapy with combination of fluvisquil. In September 2025, Furtulin was granted an additional indication in China for use in adult patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with aromatase inhibitors as initial endocrine therapy.